Pharmaceutical - Respiratory and Pulmonary


Current filters:

Respiratory and Pulmonary

Popular Filters

301 to 309 of 309 results

Mylan to acquire Pfizer generic respiratory delivery platform; challenge to GSK


US generic drug major Mylan (Nasdaq: MYL) has entered into an agreement with global pharma behemoth Pfizer…

Advair DiskusGenericsGlaxoSmithKlineLicensingMylan LaboratoriesPfizerPharmaceuticalRespiratory and PulmonarySeretide

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis


The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017


The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

Vectura shares fall as partner Novartis reports US delay for lung cancer drug


Shares of UK-based Vectura (LSE: VEC) tumbled 22% at 66 pence on Tuesday, after the company revealed…

NovartisPharmaceuticalRegulationResearchRespiratory and PulmonarySeebriVectura

Flutiform review to take longer than expected, says SkyePharma


UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization…

EuropeFlutiformMundi InternationalPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Insmed tumbles as FDA continues hold on Ph III Arikace trial


US biopharmaceutical company Insmed (Nasdaq CM: INSM) saw its share price plunge 32% to $2.95 in morning…

ArikaceBiotechnologyInsmedNorth AmericaPharmaceuticalRegulationResearchRespiratory and Pulmonary

Boehringer Ingelheim’s Combivent Respimat Inhalation Spray OKed in USA to replace aerosol


The US Food and Drug Administration has approved German independent drug major Boehringer Ingelheim’s…

Boehringer IngelheimCombiventNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

Almirall launches Nycomed’s COPD drug roflumilast in Spain; revises guidance


Spain’s largest pharma company Almirall (ALM. MC) has just launched in Spain the second brand of…

AlmirallEuropeFinancialMarkets & MarketingPharmaceuticalRespiratory and Pulmonaryroflumilast

301 to 309 of 309 results

Back to top